Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Columbia University Irving Medical Center · University Hospitals Cleveland Medical Center · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,216
total citations
- FWCI
- 46.67
- Percentile
- 100%
- References
- 29
Citations per year
Authors
30- ZZZhenfeng Zhang
Columbia University Irving Medical Center, University Hospitals Cleveland Medical Center, Case Western Reserve University
- JCJae Cheol Lee
Asan Medical Center, University of Ulsan
- LLLuping Lin
University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
- VOVictor Olivas
University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
- VAValerie Au
Columbia University Irving Medical Center
Topics & keywords
Topics
Keywords
- Erlotinib
- T790M
- Cancer research
- Lung cancer
- Biology
- GAS6
- Tyrosine kinase
- AXL receptor tyrosine kinase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.